强生(JNJ)
搜索文档
What To Expect From JNJ Stock In 2025?
Forbes· 2025-01-11 00:19
CHINA - 2023/11/11: In this photo illustration, the American multinational medical devices and ... [+] pharmaceutical company Johnson & Johnson (J&J, NYSE: JNJ) logo seen displayed on a smartphone with an Artificial intelligence (AI) chip and symbol in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...
FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab
ZACKS· 2025-01-10 22:25
Johnson & Johnson (JNJ) announced that the FDA has accepted its regulatory filing seeking the FDA's approval for nipocalimab, its investigational neonatal Fc receptor (FcRn) blocker, in generalized myasthenia gravis (gMG) indication. The filing has been granted priority review by the FDA, bringing down the review period by four months. We expect a final decision in the third quarter of 2025. The FDA filing is supported by data from the phase III Vivacity-MG3 study, which evaluated nipocalimab in adults with ...
4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025
The Motley Fool· 2025-01-10 22:00
These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal portfolio anchor stocks for a long-term investor. Here are four examples of stocks that can anchor a diversified portfolio. These stocks all trade at appealing valuations, making them a great way to kick off 2025 with a bang. 1. Microsoft You will want to build your portfolio the right way if you're going to make money with stocks over the long haul. You wouldn't build your house on a s ...
J&J Pauses Sales of Atrial Fibrillation Device, Stock Down
ZACKS· 2025-01-09 22:35
Johnson & Johnson’s (JNJ) MedTech unit has temporarily paused sales of Varipulse, its pulsed field ablation (PFA) therapy to treat atrial fibrillation (AFib) in the United States, as it investigates four reported cases of neurovascular events. The pause on Varipulse procedures began on Jan. 5. The FDA had approved the Varipulse platform in November last year.The cases were related to an external rollout plan conducted by J&J. Since the beginning of the external rollout till Jan. 3, J&J completed more than 1 ...
Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis
Prnewswire· 2025-01-09 21:04
Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad population of antibody positive adult patients: anti-AChR, anti-MuSK, anti-LRP4 SPRING HOUSE, Pa., Jan. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment of antibody po ...
Johnson & Johnson: A Potential Beneficiary Of A Great Rotation
Seeking Alpha· 2025-01-08 11:28
Johnson & Johnson (NYSE: JNJ ) (NEOE: JNJ:CA ) started this year at the same price as it started 2020. Four years of no price appreciation is hardly an attractive proposition, even with a decent dividend. This article looks at why JNJ has stagnated, andMy approach is long-term and I focus on investing in macro ideas through low risk ETFs and CEFs. I have traded stocks and currencies for nearly ten years and currently run a family fund with my partner and fellow SA contributor Andrew McElroy. I also invest i ...
Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors
ZACKS· 2025-01-08 07:51
Johnson & Johnson (JNJ) closed at $146.18 in the latest trading session, marking a +1.75% move from the prior day. The stock outpaced the S&P 500's daily loss of 1.11%. Elsewhere, the Dow saw a downswing of 0.42%, while the tech-heavy Nasdaq depreciated by 1.89%.Heading into today, shares of the world's biggest maker of health care products had lost 3.97% over the past month, outpacing the Medical sector's loss of 6.22% and lagging the S&P 500's loss of 1.7% in that time.Investors will be eagerly watching f ...
Johnson & Johnson: I'm Saying Yes To This Mess
Seeking Alpha· 2025-01-08 00:00
Johnson & Johnson (NYSE: JNJ ) is a one big enigma right now. And I like it. I’ve owned it since May and it has been a experience not unlike many I have had with other high quality dividend stocks. It isI'm Rob Isbitts, founder of Sungarden Investment Publishing. I run the new investing group Sungarden YARP Portfolio, a community dedicated to navigating the modern investment climate with humility, discipline, and a non-traditional approach to income investing. I've been charting investments since the 1980s, ...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib
Prnewswire· 2025-01-07 21:00
Median overall survival improvement expected to exceed one yearFirst and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancerRARITAN, N.J., Jan. 7, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced positive topline results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study, evaluating RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) as a first-line therapy for p ...
J&J Trading Near 52-Week Low: Should You Sell the Stock?
ZACKS· 2024-12-31 00:51
J&J’s (JNJ) stock closed at $145.05 on Friday, quite close to its 52-week low of $142.75. In the past three months, J&J’s stock has lost more than 10%.Slowing sales of J&J’s MedTech segment, the upcoming patent expiration of its blockbuster drug, Stelara and talc-related legal issues are some of J&J’s main concerns. The overall drug and biotech sector saw a major downturn in the second half of the year due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment ...